Literature DB >> 10398178

Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma.

T E Merchant1, B H Kushner, J M Sheldon, M LaQuaglia, J H Healey.   

Abstract

BACKGROUND: As an alternative to high-dose irradiation, limited surgery and low-dose irradiation have been investigated as a means to achieve local control. We retrospectively examined the clinical characteristics, treatment, and outcome for 25 patients with Ewing sarcoma treated with limited surgery and low-dose irradiation. PROCEDURE: The records of 25 patients (age 4-48 years) were reviewed who were treated between 1979 and 1996 at Memorial Sloan-Kettering Cancer Center. At the time of diagnosis, 21 of the 25 patients had prognostically unfavorable tumors including the presence of metastatic disease (n = 12), an axial primary (n = 17), and a tumor measuring greater than 8 cm (n = 18). The primary tumor was completely resected (wide local excision) in 13 patients, incompletely resected (marginal excision) in 7 patients, and biopsied only in the remaining 5 patients. The median dose of irradiation to the primary site was 30 Gy.
RESULTS: With a median follow-up of 67 months (range 16-189 months) for the surviving patients, 28% failed distantly, and an additional 28% suffered from the progression of previously established metastatic disease. No patient failed locally. The median overall survival was 43 months. The actuarial overall survival at 5 years was 39% (+/-11%) for all patients and 60% (+/-14%) for patients with localized disease.
CONCLUSIONS: Limited surgery and postoperative irradiation are one strategy that promises to balance the goal of achieving local control with the goal of diminishing late effects. Apart from the scenario in which radiation therapy is absolutely unnecessary, low-dose irradiation may be appropriate after considering the risk for local recurrence and overall prognosis. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10398178     DOI: 10.1002/(sici)1096-911x(199908)33:2<65::aid-mpo1>3.0.co;2-l

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

1.  Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Robert Mennel; Carl Lenarsky; Staci Horvath; Gladice Wallraven; Beena O Pappen; Sam Whiting; Donald Rao; Neil Senzer; John Nemunaitis
Journal:  Mol Ther       Date:  2016-04-25       Impact factor: 11.454

Review 2.  Ewing tumour: incidence, prognosis and treatment options.

Authors:  M Paulussen; B Fröhlich; H Jürgens
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  High Efficacy of Preoperative Low-Dose Radiotherapy with Sanazole (AK-2123) for Extraskeletal Ewing's Sarcoma: A Case Report.

Authors:  Tomoya Sakabe; Hiroaki Murata; Eiichi Konishi; Kazutaka Koto; Naoyuki Horie; Takaaki Matsui; Yasushi Sawai; Hideya Yamazaki; Tsutomu V Kagiya; Toshikazu Kubo
Journal:  Sarcoma       Date:  2010-09-06

Review 4.  Ewing's sarcoma.

Authors:  P A Meyers; A S Levy
Journal:  Curr Treat Options Oncol       Date:  2000-08

5.  Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone.

Authors:  B S Margulies; S D DeBoyace; T A Damron; M J Allen
Journal:  Bone       Date:  2015-06-05       Impact factor: 4.398

6.  Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.

Authors:  Donald D Rao; Christopher Jay; Zhaohui Wang; Xiuquan Luo; Padmasini Kumar; Hilary Eysenbach; Maurizio Ghisoli; Neil Senzer; John Nemunaitis
Journal:  Mol Ther       Date:  2016-05-11       Impact factor: 11.454

7.  Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.

Authors:  Hampartsoum B Barsoumian; Rishab Ramapriyan; Ahmed I Younes; Mauricio S Caetano; Hari Menon; Nathan I Comeaux; Taylor R Cushman; Jonathan E Schoenhals; Alexandra P Cadena; Timothy P Reilly; Dawei Chen; Fatemeh Masrorpour; Ailin Li; David S Hong; Adi Diab; Quynh-Nhu Nguyen; Isabella Glitza; Renata Ferrarotto; Stephen G Chun; Maria Angelica Cortez; James Welsh
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.